These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37020276)

  • 21. Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis.
    Jacobson JC; Qiao J; Clark RA; Chung DH
    Discov Oncol; 2022 Oct; 13(1):103. PubMed ID: 36227363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.
    Landais I; Hiddingh S; McCarroll M; Yang C; Sun A; Turker MS; Snyder JP; Hoatlin ME
    Mol Cancer; 2009 Dec; 8():133. PubMed ID: 20043851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
    Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
    Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Fanconi anemia ID2 complex: dueling saxes at the crossroads.
    Boisvert RA; Howlett NG
    Cell Cycle; 2014; 13(19):2999-3015. PubMed ID: 25486561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
    Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
    Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
    Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
    J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
    Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
    BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
    Williamson CT; Muzik H; Turhan AG; Zamò A; O'Connor MJ; Bebb DG; Lees-Miller SP
    Mol Cancer Ther; 2010 Feb; 9(2):347-57. PubMed ID: 20124459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
    Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP
    EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
    Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
    J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
    Quijada-Álamo M; Hernández-Sánchez M; Alonso-Pérez V; Rodríguez-Vicente AE; García-Tuñón I; Martín-Izquierdo M; Hernández-Sánchez JM; Herrero AB; Bastida JM; San Segundo L; Gruber M; García JL; Yin S; Ten Hacken E; Benito R; Ordóñez JL; Wu CJ; Hernández-Rivas JM
    Leukemia; 2020 Jun; 34(6):1599-1612. PubMed ID: 31974435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
    Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
    Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.
    Taniguchi T; Garcia-Higuera I; Xu B; Andreassen PR; Gregory RC; Kim ST; Lane WS; Kastan MB; D'Andrea AD
    Cell; 2002 May; 109(4):459-72. PubMed ID: 12086603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells.
    Burdak-Rothkamm S; Rothkamm K; McClelland K; Al Rashid ST; Prise KM
    Cancer Lett; 2015 Jan; 356(2 Pt B):454-61. PubMed ID: 25304378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
    Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K
    Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
    Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
    J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response.
    Min A; Jang H; Kim S; Lee KH; Kim DK; Suh KJ; Yang Y; Elvin P; O'Connor MJ; Im SA
    Mol Cancer Ther; 2018 Dec; 17(12):2507-2518. PubMed ID: 30232143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.